Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.

van de Loosdrecht, A A; van den Ancker, W; Houtenbos, I; Ossenkoppele, G J; Westers, T M

van de Loosdrecht, A A; van den Ancker, W; Houtenbos, I; Ossenkoppele, G J; Westers, T M.

Affiliation

van de Loosdrecht AA; Department of Haematology, VU-Institute of Cancer and Immunology, VU University Medical Center, Amsterdam, De Boelelaan 1117, 1081 HV, The Netherlands. A.vandeloosdrecht@vumc.nl

Handb Exp Pharmacol ; (188): 319-48, 2009.

Article in En | MEDLINE | ID: mdl-19031033

Subject(s)

Adjuvants, Immunologic/therapeutic use; Cancer Vaccines; Dendritic Cells/transplantation; Immunotherapy, Adoptive; Leukemia, Myeloid/therapy; Animals; Antigen Presentation; Cell Line, Tumor; Cytokines/metabolism; Dendritic Cells/immunology; Histocompatibility Antigens/metabolism; Humans; Immunological Synapses; Leukemia, Myeloid/immunology; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating/immunology; Signal Transduction; T-Lymphocytes/immunology; Treatment Outcome; Tumor Escape

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Dendritic Cells / Leukemia, Myeloid / Adjuvants, Immunologic / Immunotherapy, Adoptive / Cancer Vaccines Limits: Animals / Humans Language: En Year: 2009 Type: Article

Fulltext

XML

PubMed Links

Search on Google